| Additional Diagnosis opportunities with the novel cardiac marker GPBB Diagenics International Corporation starts its first extensive study project in collaboration with its latest partner, the German Myocardial Infarction Research Institute (IHF). [external Link] Heart attack - new method offers rapid diagnosis According to the World Health Organization heart attack is one of the most common causes of death. With a novel diagnostic method the investigation process should be accelerated in order to initiate rescue operations faster. [external Link] Diagenics/Nanomedics in Biotech journal "Nanomedics (Duesseldorf, Germany) , another development-stage company targeting the POC cardiac marker market and founded in 2002, is a subsidiary of Diagenics (Woburn, Massachusetts). Diagenics has introduced the Diacordon laboratory-based ELISA test for the cardiac marker Glycogen Phosphorylase isoenzyme BB (GPBB) in Europe, and its Nanomedics division, is now developing a POC version of the assay, as well as a troponin I assay and other cardiac marker tests, based on a biochip platform. "Diagenics with Biochip against heart infarction" The German – American biopharmaceutical company Diagenics (Duesseldorf/Boston) announced the development of a biochip for the diagnosis of heart infarctions. Thus the gap in early diagnosis is closed and a quicker treatment is allowed. "Governor Jeb Bush invites Diagenics in Florida" During his visit to Europe, Jeb Bush, Governor of Florida, met decision makers in Switzerland and Germany. His clear strategy: to bring innovative high tech industry to Florida. He looked particularly for companies in the IT field as well as in Life Sciences incl. the pharmaceutical and biotechnology industry. [external Link] or [pdf-Download] "One drop of blood is enough" Heart infarction can now be clearly diagnosed with the detection of the Glycogenphosphorylase enzyme in blood quicker than with the troponin test, for which Boehringer Mannheim (today Roche) received the innovation prize of German Science in 1995. Such a test kit was developed by the German – American Diagenics and the Californian Millenia Diagnostics. [pdf-Download] "New blood test diagnoses heart infarction earlier" The diagnosis of an infarction should occur as soon as possible. The first four hours after the infarction are decisive. Still, the detection of a heart infarction is difficult. Thus analysis procedures which detect proteins and enzymes in the blood – heart markers – the body releases after injury of the heart muscles.[external Link] oder [pdf-Download] |
Produkte
DIACORDON - POCT
POINT-OF-CARE TEST
The Point Of Care Test (POCT) is the successor of the ELISA Test and an important supplement for the emergency ambulances. It is a quick and qualitative test for making the first decisions. Point Of Care Tests are always advantageous, since they can provide a diagnosis without the laboratory support.
DIACORDON™ POCT is a stripe test (lateral flow), which also functions on the GPBB basis. Its various layers are plated with small traces of monoclonal catch-antibody of GPBB. Another antibody, responsible for the colouring, is applied on the other side. Once the blood sample runs on the absorbent strap on the antibody track, GPBB is caught by the antibodies and made visible with the help of the antibody colouring. 50 µl are enough to gain a solid result. The time for testing only takes about 15 minutes.
Until now there is no early and reliable heart specific test. Therefore, it is very difficult for doctors to rule out an infarction incidence without invasive diagnostics. Diagenics offers its patented GPBB blood test for an indication group, which knows no other alternatives. Thus, DIACORDON™ is progressive in the field of heart diseases diagnostics.
Another interesting patient group endorses those who had an open heart operation and who often suffer from a destruction of the heart muscle cells under use of a heart-lung machine. DIACORDON™ can help monitoring these patients within the first 12 to 18 hours (as long as GPBB is traceable) after the operation.
The well defined goal of Diagenics is to establish DIACORDON™ as a “gold standard” for the diagnosis and monitoring of myocardial ischemia. Once the first results can be confirmed, the test can be initiated for use as a rapid test in ambulances, in emergency rooms, in doctor offices or next to the patient bed.
The test is simple, fast, safe, dependable and sensitive. At the moment there are discussions with leading active pharmaceutical companies concerning its marketing worldwide.
DIACORDON - ELISA
LABORATORY TEST
DIACORDON™ is a blood test for the early detection of cardiac infarction. It works on an enzyme basis and can detect Glycogen-Phosphorylase Isoenzym BB (GPBB) via an antibody owned by Diagenics.
The enzyme GPBB enters the bloodstream as soon as a myocardial ischemia occurs. In the long run such an insufficient oxygen supply leads to a necrosis of the affected cells and/or eventually to an infarction. Moreover, the detection of GPBB in the blood provides information about the progress of the coronary syndromes (including unstable angina pectoris) and classic cases of heart attack. In this way it contributes decisively to the diagnosis of heart infarction patients.
There are already markers, such as myoglobin and troponin, which contribute to the diagnosis and are routinely applied in cases of a myocardial infarction. Myoglobin, however, has the disadvantage of not being heart specific. It can also be detected after damages of the skeletal muscles or after acute renal failure and thus does not give a clear answer. Troponin, on the other hand, is heart specific, but can only be detected three to six hours after the first symptoms (chest pain).
GPBB is not only heart specific but also early detectable, i.e. within the first hour. For the case of acute coronary syndromes this is a vital advantage, since a quick and exact diagnosis can save lives.
|
Press releases
|
|